Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]6b
- Development stage
- Unknown
- Lead developer
- University of Pennsylvania
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[18F]6b is an experimental radiopharmaceutical developed as a positron emission tomography (PET) tracer for the in vivo imaging of alpha-synuclein (α-syn) aggregates. Alpha-synuclein misfolding and aggregation are hallmark features of synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The tracer is a phenothiazine derivative designed to cross the blood-brain barrier and bind with high affinity and selectivity to α-synuclein fibrils over other protein aggregates such as amyloid-beta or tau. By enabling the visualization and quantification of α-synuclein pathology in the living brain, [18F]6b aims to facilitate early diagnosis, monitor disease progression, and serve as a biomarker for evaluating the efficacy of alpha-synuclein-targeting therapies in clinical trials.
- Other names
- 18F-labeled phenothiazine derivative 6b
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))
Beyond the preview
Go deeper on [18F]6b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]6b.